Most cited article - PubMed ID 18311685
Tiagabine treatment is associated with neurochemical, immune and behavioural alterations in the olfactory bulbectomized rat model of depression
Ketamine may prove to be a potential candidate in treating the widespread drug addiction/substance abuse epidemic among patients with schizophrenia. Clinical studies have shown ketamine to reduce cocaine and heroin cravings. However, the use of ketamine remains controversial as it may exacerbate the symptoms of schizophrenia. Therefore, the aim of this study is to characterize the effects of ketamine on drug addiction in schizophrenia using the methylazoxymethanol (MAM) acetate rat model on operant IV methamphetamine (METH) self-administration. MAM was administered intraperitoneally (22 mg/kg) on gestational day 17. Locomotor activity test and later IV self-administration (IVSA) were then performed in the male offspring followed by a period of forced abstinence and relapse of METH taking. After reaching stable intakes in the relapse phase, ketamine (5 mg/kg) was administered intraperitoneally 30 min prior to the self-administration session. As documented previously, the MAM rats showed a lack of habituation in the locomotor activity test but developed stable maintenance of METH self-administration with no difference in operant behaviour to control animals. Results show that ketamine treatment significantly reduced the METH intake in the control animals but not in MAM animals. Ketamine effect on METH self-administration may be explained by increased glutamatergic signalling in the prefrontal cortex caused by the N-methyl-D-aspartate antagonism and disinhibition of GABA interneurons which was shown to be impaired in the MAM rats. This mechanism may at least partly explain the clinically proven anti-craving potential of ketamine and allow development of more specific anti-craving medications with fewer risks.
- Keywords
- Ketamine, MAM model, Methamphetamine, Self-administration, Sprague-Dawley rats,
- MeSH
- Analysis of Variance MeSH
- Self Administration MeSH
- Ketamine pharmacology toxicity MeSH
- Rats MeSH
- Locomotion drug effects MeSH
- Methamphetamine administration & dosage MeSH
- Methylazoxymethanol Acetate analogs & derivatives toxicity MeSH
- Disease Models, Animal MeSH
- Conditioning, Operant drug effects MeSH
- Rats, Sprague-Dawley MeSH
- Schizophrenia chemically induced drug therapy MeSH
- Central Nervous System Stimulants administration & dosage MeSH
- Dose-Response Relationship, Drug MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Ketamine MeSH
- Methamphetamine MeSH
- methylazoxymethanol MeSH Browser
- Methylazoxymethanol Acetate MeSH
- Central Nervous System Stimulants MeSH